Global Genomic Analysis of Prostate, Breast and Pancreatic Cancer
Addendum to final rept. 16 Sep 2010-15 Sep 2012
HUDSONALPHA INST FOR BIOTECHNOLOGY HUNTSVILLE AL
Pagination or Media Count:
Prostate cancer and breast cancer are the most prevalent cancers in men and women, respectively, and pancreatic cancer, while more rare than prostate and breast cancer, is an extremely lethal cancer, with a 5-year survival rate of less than 5. With the recent advances in next generation sequencing technology, there is an opportunity to identify genomic aberrations that will provide knowledge about the biology driving these cancers and serve as novel diagnostic and prognostic biomarkers for these diseases. We performed genome-wide measurements of mRNA, microRNA, and DNA methylation from tumor and patient-matched non-tumor tissues. We have identified DNA methylation and gene expression signatures associated tumor formation, disease recurrence, and treatment sensitivity. These candidate biomarkers may be useful in predicting clinical outcomes for patients, and may suggest pathways that can be targeted with novel treatment regimens.
- Anatomy and Physiology
- Medicine and Medical Research